Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49:1476–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2:366–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72:5454–62.

Article  CAS  PubMed  Google Scholar 

Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.

Article  CAS  PubMed  Google Scholar 

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.

Article  CAS  PubMed  Google Scholar 

Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78–94.

Article  CAS  PubMed  Google Scholar 

Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat Commun. 2017;8:857.

Article  PubMed  PubMed Central  Google Scholar 

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–2505.

Article  CAS  PubMed  Google Scholar 

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–28.

Article  CAS  PubMed  Google Scholar 

Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–402.

Article  CAS  PubMed  Google Scholar 

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Monk BJ, Parkinson C, Lim MC, O’Malley DM, Oaknin A, Wilson MK, et al. A Randomized, Phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;40:3952–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): a randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5). Gynecol Oncol. 2022;166:S50–1.

Article  Google Scholar 

Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, et al. Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1/ENGOT-ov25 trial. JCO Precis Oncol. 2023;7:e2200258.

Article  PubMed  PubMed Central  Google Scholar 

Pujade-Lauraine E, Christinat Y, D’incalci M, Schouten P, Buisson A, Heukamp L, et al. 201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative. Int J Gynecol Cancer. 2021;31:A208.

Google Scholar 

Eeckhoutte A, Houy A, Manie E, Reverdy M, Bieche I, Marangoni E, et al. ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. Bioinformatics. 2020;36:3888–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray-Coquard IL, Leary A, Pignata S, Cropet C, Gonzalez Martin AJ, Bogner G, et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). Ann Oncol. 2022;33:S808–69.

Article  Google Scholar 

Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, et al. Concordance between tumor and germline BRCA status in high-grade ovarian carcinoma patients in the phase III PAOLA-1/ENGOT-ov25 trial. J Natl Cancer Inst. 2021;113:917–23.

Article  PubMed  Google Scholar 

Popova T, Manie E, Boeva V, Battistella A, Goundiam O, Smith NK, et al. Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res. 2016;76:1882–91.

Article  CAS  PubMed  Google Scholar 

Coussy F, Bidard FC. Expanding biomarkers for PARP inhibitors. Nat Cancer. 2022;3:1141–3.

Article  CAS  PubMed  Google Scholar 

Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat Cancer. 2022;3:1181–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, et al. Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial. JAMA Oncol. 2022;8:1802–8.

Article  PubMed  PubMed Central  Google Scholar 

Loverix L, Vergote I, Busschaert P, Vanderstichele A, Venken T, Boeckx B, et al. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. Eur J Cancer. 2023;188:131–9.

Article  CAS  PubMed  Google Scholar 

Willing E-M, Vollbrecht C, Voessing C, Weist P, Schallenberg S, Jori B, et al. 2022-RA-873-ESGO validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial. Int J Gynecol Cancer. 2022;32:A370.

Google Scholar 

Buisson A, Saintigny P, Harle A, Vacirca D, Barberis M, Gilson P, et al. 2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection. Int J Gynecol Cancer. 2022;32:A277–8.

Google Scholar 

Leman R, Muller E, Goardon N, Chentli I, Tranchant A, Legros A, et al. 2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers. Int J Gynecol Cancer. 2022;32:A280.

Google Scholar 

Christinat Y, Ho L, Clément S, Genestie C, Sehouli J, Martin AG, et al. 2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial. Int J Gynecol Cancer. 2022;32:A238–9.

Google Scholar 

Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012;28:423–5.

Article  CAS  PubMed  Google Scholar